Skin autofluorescence and all-cause mortality in stage 3 CKD

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 8, 2014, Pages 1361-1368

  Fraser, Simon D S ^a   Roderick, Paul J ^a   McIntyre, Natasha J ^b   Harris, Scott ^a   McIntyre, Christopher W ^c   Fluck, Richard J ^b   Taal, Maarten W ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b ROYAL DERBY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HEMOGLOBIN; ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER;

ADULT; AGED; ALBUMINURIA; ARTICLE; AUTOFLUORESCENCE; BLOOD ANALYSIS; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; DIABETES MELLITUS; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HYPERTENSION; INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; NEOPLASM; PREVALENCE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; SENSITIVITY ANALYSIS; SKIN AUTOFLUORESCENCE; SKIN COLOR; SMOKING; STAGING; SURVIVAL; TREATMENT OUTCOME; URINALYSIS; VERY ELDERLY; CAUSE OF DEATH; CHEMISTRY; CHI SQUARE DISTRIBUTION; LUMINESCENCE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; SKIN; TIME;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KAPLAN-MEIER ESTIMATE; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SKIN; TIME FACTORS;

EID: 84923786799     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09510913     Document Type: Article

References (44)

1. Noordzij MJ, Lefrandt JD, Smit AJ: Advanced glycation end products in renal failure: An overview. J Ren Care 34: 207–212, 2008.
2. McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW: Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. Clin J Am Soc Nephrol 6: 2356–2363, 2011.
3. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405–412, 1991.
4. Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H: Diet-derived advanced glycation end products are major contributors to the body’s AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 1043: 461–466, 2005.
5. Treweek JB, Dickerson TJ, Janda KD: Drugs of abuse that mediate advanced glycation end product formation: A chemical link to disease pathology. Acc Chem Res 42: 659–669, 2009.
6. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H: Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 94: 6474–6479, 1997.
7. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, van Ypersele de Strihou C: Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 51: 1170–1181, 1997.
8. Baynes JW: From life to death—the struggle between chemistry and biology during aging: TheMaillard reaction as an amplifier of genomic damage. Biogerontology 1: 235–246, 2000.
9. Linden E, Cai W, He JC, Xue C, Li Z, Winston J, Vlassara H, Uribarri J: Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)- mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol 3: 691–698, 2008.
10. D’Agati V, Schmidt AM: RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol 6: 352–360, 2010.
11. Lindsey JB, Cipollone F, Abdullah SM, McGuire DK: Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): Cardiovascular implications. Diab Vasc Dis Res 6: 7–14, 2009.
12. Busch M, Franke S, Rüster C, Wolf G: Advanced glycation endproducts and the kidney. Eur J Clin Invest 40: 742–755, 2010.
13. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans RO, Smit AJ: Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 47: 1324–1330, 2004.
14. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR: Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 314: 403–408, 1986.
15. Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, Smit AJ: Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 29: 2654–2659, 2006.
16. Hartog JW, Hummel YM, Voors AA, Schalkwijk CG, Miyata T, Huisman RM, Smit AJ, Van Veldhuisen DJ: Skin-autofluorescence, a measure of tissue advanced glycation end-products (AGEs), is related to diastolic function in dialysis patients. J Card Fail 14: 596–602, 2008.
17. Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO, Smit AJ: Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30: 107–112, 2007.
18. Lutgers HL, Gerrits EG, Graaff R, Links TP, Sluiter WJ, Gans RO, Bilo HJ, Smit AJ: Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 52: 789–797, 2009.
19. Ueno H, Koyama H, Tanaka S, Fukumoto S, Shinohara K, Shoji T, Emoto M, Tahara H, Kakiya R, Tabata T, Miyata T, Nishizawa Y: Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism 57: 1452–1457, 2008.
20. Meerwaldt R, Hartog JWL, Graaff R, Huisman RJ, Links TP, den Hollander NC, Thorpe SR, Baynes JW, Navis G, Gans ROB, Smit AJ: Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 16: 3687–3693, 2005.
21. Arsov S, Trajceska L, van Oeveren W, Smit AJ, Dzekova P, Stegmayr B, Sikole A, Rakhorst G, Graaff R: Increase in skin autofluorescence and release of heart-type fatty acid binding protein in plasma predicts mortality of hemodialysis patients. Artif Organs 37: E114–E122, 2013.
22. Crowley LE, Johnson CP, McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW, Leung JC: Tissue advanced glycation end product deposition after kidney transplantation. Nephron Clin Pract 124: 54–59, 2013.
23. Jordan H, Roderick P, Martin D: The Index of Multiple Deprivation 2000 and accessibility effects on health. J Epidemiol Community Health 58: 250–257, 2004.
24. Grundy E, Holt G: The socioeconomic status of older adults:How should we measure it in studies of health inequalities? J Epidemiol Community Health 55: 895–904, 2001.
25. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF II, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612, 2009.
26. Pinto-Sietsma SJ, Navis G, Janssen WMT, de Zeeuw D, Gans ROB, de Jong PE; PREVEND Study Group: A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis 41: 733–741, 2003.
27. The World Health Organization and International Diabetes Federation: The Definition and Diagnosis of Diabetes Mellitus and Intermediate Glycaemia, Geneva, Switzerland,WHOPress, 2006.
28. Hegab Z, Gibbons S, Neyses L, Mamas MA: Role of advanced glycation end products in cardiovascular disease. World J Cardiol 4: 90–102, 2012.
29. de Vos LC, Noordzij MJ, Mulder DJ, Smit AJ, Lutgers HL, Dullaart RP, Kamphuisen PW, Zeebregts CJ, Lefrandt JD: Skin autofluorescence as a measure of advanced glycation end products deposition is elevated in peripheral artery disease. Arterioscler Thromb Vasc Biol 33: 131–138, 2013.
30. Koyama Y, Takeishi Y, Arimoto T, Niizeki T, Shishido T, Takahashi H, Nozaki N, Hirono O, Tsunoda Y, Nitobe J, Watanabe T, Kubota I: High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail 13: 199–206, 2007.
31. Fraser SD, Roderick PJ, McIntyre NJ, Harris S, McIntyre CW, Fluck RJ, Taal MW: Socio-economic disparities in the distribution of cardiovascular risk in chronic kidney disease stage 3. Nephron Clin Pract 122: 58–65, 2012.
32. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46: 223–234, 1995.
33. Zieman SJ, Kass DA: Advanced glycation endproduct crosslinking in the cardiovascular system: Potential therapeutic target for cardiovascular disease. Drugs 64: 459–470, 2004.
34. Bidasee KR, Nallani K, Henry B, Dincer UD, Besch HR Jr.: Chronic diabetes alters function and expression of ryanodine receptor calcium-release channels in rat hearts. Mol Cell Biochem 249: 113–123, 2003.
35. Lagadic-Gossmann D, Buckler KJ, Le Prigent K, Feuvray D: Altered Ca2+ handling in ventricular myocytes isolated from diabetic rats. Am J Physiol 270: H1529–H1537, 1996.
36. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM: RAGEmediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 97: 889–901, 1999.
37. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405: 354–360, 2000.
38. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM: RAGE andamyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature 382: 685–691, 1996.
39. Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, Soto C, Schmidt AM, Stern D, Kindy M: Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 6: 643–651, 2000.
40. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS: A predictive model for progression of chronic kidney disease to kidney failure. JAMA 305: 1553–1559, 2011.
41. Collins GS, Altman DG: An independent and external validation of QRISK2 cardiovascular disease risk score: A prospective open cohort study. BMJ 340: c2442, 2010.
42. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, Brindle P: Predicting cardiovascular risk in England and Wales: Prospective derivation and validation of QRISK2. BMJ 336: 1475–1482, 2008.
43. Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ, Gans RO, Bilo HJ: Skin autofluorescence: A tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 31: 517–521, 2008.
44. Koetsier M, Nur E, Chunmao H, Lutgers HL, Links TP, Smit AJ, Rakhorst G, Graaff R: Skin color independent assessment of aging using skin autofluorescence. Opt Express 18: 14416–14429, 2010.